MESO Key Statistics, Chart & Performance
The current stock price of MESO is 18.16 USD. In the past month the price increased by 7.27%. In the past year, price decreased by -9.74%.
MESO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About MESO
Company Profile
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 81 full-time employees. The company went IPO on 2004-12-16. The firm is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The firm has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
Company Info
MESOBLAST LTD- SPON ADR
L 38 55 Collins St
Melbourne VICTORIA 3000 AU
CEO: Silviu Itescu
Employees: 73
Phone: 61396396036
MESOBLAST LTD- SPON ADR / MESO FAQ
What does MESOBLAST LTD- SPON ADR do?
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 81 full-time employees. The company went IPO on 2004-12-16. The firm is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The firm has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
What is the current price of MESO stock?
The current stock price of MESO is 18.16 USD. The price increased by 0.67% in the last trading session.
What is the dividend status of MESOBLAST LTD- SPON ADR?
MESO does not pay a dividend.
How is the ChartMill rating for MESOBLAST LTD- SPON ADR?
MESO has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting MESO stock to perform?
10 analysts have analysed MESO and the average price target is 20.25 USD. This implies a price increase of 11.49% is expected in the next year compared to the current price of 18.16.
Can you provide the growth outlook for MESOBLAST LTD- SPON ADR?
The Revenue of MESOBLAST LTD- SPON ADR (MESO) is expected to grow by 564.42% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for MESOBLAST LTD- SPON ADR?
MESOBLAST LTD- SPON ADR (MESO) has a market capitalization of 2.33B USD. This makes MESO a Mid Cap stock.
MESO Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to MESO. When comparing the yearly performance of all stocks, MESO is a bad performer in the overall market: 70.56% of all stocks are doing better.
MESO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MESO. MESO may be in some trouble as it scores bad on both profitability and health.
MESO Financial Highlights
Over the last trailing twelve months MESO reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS increased by 5.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.02% | ||
| ROE | -17.1% | ||
| Debt/Equity | 0.12 |
MESO Forecast & Estimates
10 analysts have analysed MESO and the average price target is 20.25 USD. This implies a price increase of 11.49% is expected in the next year compared to the current price of 18.16.
For the next year, analysts expect an EPS growth of 83.69% and a revenue growth 564.42% for MESO